Dalpiciclib
艾瑞康(Dalpiciclib)
A Chinese-developed CDK4/6 inhibitor pill (Hengrui).
At a glance
China price
Verified pricing is not currently available.
NRDL (national insurance)
In NRDL.
Regulatory status
NMPA approved (2021); NRDL (2022)
What this meansSupported by a credible secondary source but not yet independently confirmed against a primary source.
SourceNo independent source on file.
NotesApproval status from public regulatory reporting.
What it treats
HR+/HER2- advanced breast cancer with endocrine therapy.
Sources & verification
No independent source is currently on file. We have not independently verified this information.
Reader discussion
Public comments about Dalpiciclib. Discussion is not medical advice, and a comment is not an endorsement or a verified fact. Open the full forum.